Trial Profile
Phase III study of Labetuzumab-govitecan in patients with metastatic colorectal cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2016
Price :
$35
*
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Immunomedics
- 07 Jan 2016 New trial record